polycystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: (phenotype A): cyproterone compound tablets (21 days in each monthly cycle, for 3 months) along with Lactofem capsules (500 mg, manufactured by Zit-takhammir, Iran,
Sponsors
Yasouj University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: age 18 to 40 years Confirmation of polycystic ovary syndrome based on the Rotterdam criteria Iranian Absence of severe mental conditions since six months before the research Not suffering from severe depression and anxiety according to the depression and anxiety questionnaire No language or cognitive problems preventing the patient from completing the questionnaire No current use of drugs affecting sexual function No smoking Failure to previously diagnose an organic cause for sexual dysfunction by an experienced physician No current use of psychiatric medications Currently taking cyproterone compound tablets as prescribed by the gynecologist
Exclusion criteria
Exclusion criteria: Patients who do not want to cooperate Pregnancy during study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sexual function. Timepoint: Before the intervention and three after the intervention. Method of measurement: FSFI sexual function questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Asadi
Yasouj University of Medical Sciences
Outcome results
None listed